08:48 AM EST - Oncolytics Biotech Inc : Announced an upcoming poster presentation that will feature the follow-up results from ReoGlio, an investigator-sponsored, phase 1b trial evaluating the combination of pelareorep and granulocyte-macrophage colony-stimulating factor alongside standard chemoradiotherapy and adjuvant temozolomide for the treatment of glioblastoma multiforme. The poster will be presented at the American Association for Cancer Research Annual Meeting 2022, which is taking place both virtually and in-person at the Ernest N. Morial Convention Center in New Orleans from April 8-13, 2022. Oncolytics Biotech Inc
shares T.ONC are trading up $0.05 at $2.02.
